Letermovir Patent Expiration
Letermovir was first introduced by Merck Sharp And Dohme Corp
Letermovir Patents
Given below is the list of patents protecting Letermovir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Prevymis | US10603384 | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative | Feb 28, 2033 | Merck Sharp Dohme |
| Prevymis | USRE46791 | Substituted dihydroquinazolines | Jan 18, 2029 | Merck Sharp Dohme |
| Prevymis | USRE46791 | Substituted dihydroquinazolines | Jan 18, 2029 | Msd |
| Prevymis | US7196086 | Substituted dihydroquinazolines |
May 22, 2024
(Expired) | Merck Sharp Dohme |
| Prevymis | US8513255 | Substituted dihydroquinazolines |
May 22, 2024
(Expired) | Merck Sharp Dohme |
Letermovir's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Letermovir:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077) | Merck Sharp & Dohme LLC | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. | ModernaTX, Inc. | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell | M.D. Anderson Cancer Center | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT | University of California, Irvine | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant | City of Hope Medical Center | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1 |